Organon stock highlights VTAMA data ahead of its clinical conference

Published on 10/07/2026 at 00:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Organon stock was last at USD 13.74 on October 6, 2026, near its 52-week high of USD 13.79. Q2 profit was USD 108.0 million.

OGN, US68622V1061, Illustration mit AI erstellt.

Organon stock was last at USD 13.74 on the NYSE on October 6, 2026, up 0.29 percent from the prior close and only USD 0.05 below its 52-week high of USD 13.79. The company is putting new VTAMA real-world data before specialists, giving the market a fresh product-development checkpoint.

VTAMA data sharpen the pipeline story

According to Organon on October 1, 2026, a new real-world analysis of VTAMA cream in patients with atopic dermatitis was scheduled for presentation at the 2026 Fall Clinical Dermatology Conference. The analysis covers physician-reported body-surface-area and global-assessment outcomes, as well as patient-reported itch scores.

Organon describes VTAMA as an approved treatment for plaque psoriasis in adults and atopic dermatitis in adults and pediatric patients aged 2 and older. The product matters because the portfolio also carries pressure from mature medicines and patent expiries, making new-product adoption central to the revenue outlook.

Q2 margins add a counterweight

Q2 2026 delivered USD 1.558 billion in revenue and USD 108.0 million in profit, while net margin narrowed to 6.9 percent from 9.1 percent. Simply Wall St reported those Q2 2026 figures on September 30, 2026, highlighting the contrast between product growth hopes and weaker profitability.

That contrast is important for investors because the VTAMA analysis addresses clinical effectiveness, while the Q2 figures measure the financial conversion of the broader portfolio. A stronger commercial contribution from newer products would need to offset pricing pressure and loss-of-exclusivity effects across established therapies.

Analysts keep a cautious valuation

MarketBeat reported on September 18, 2026, that seven research firms carried a Reduce consensus, including five Hold ratings and two Sell ratings. The average 12-month price target was USD 11.40, which is USD 2.34 below the October 6 price of USD 13.74.

The valuation gap places greater weight on execution than on the headline share price. Organon's market capitalization was USD 3.6 billion on October 6, 2026, while trading volume reached 1,948,911 shares.

Organon stock stays near its yearly high

Organon stock was last at USD 13.74 on the NYSE on October 6, 2026, with a 52-week range of USD 5.69 to USD 13.79. The next market test is whether VTAMA and other newer products can improve the earnings profile reflected in the Q2 margin comparison.